Clin2
NCT03082755Possibly a fitRecruiting

Study sleep agitation and restless legs in Alzheimer’s patients

Alzheimer Disease

Part of Brain & nervous system, Mental health clinical trials.

This trial studies treatment for troubling nighttime restlessness and agitation in people with Alzheimer’s disease. It may help improve sleep and nighttime comfort and reduce nighttime behavior problems.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
156 people
Ages
55 years and older
Study type
Interventional

Who can take part

  • You are age 55 or older
  • A doctor has diagnosed Alzheimer’s disease, and you have mild to severe dementia (CDR 0.5 to 3)
  • You have significant nighttime agitation and restless legs symptoms (as measured by study questionnaires/checks)
  • Your medicines are stable for at least 14 days (no recent big changes), and you don’t have signs of a sudden illness like fever or delirium
  • You can swallow the study medicine and you can get around (walk with or without help)
  • You have a live-in caregiver (family or hired), not just living alone

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06808984Recruiting· Phase 2
Testing a new drug for agitation in Alzheimer's disease

This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.

Homewood, Alabama
NCT05543681Recruiting· Phase 2
Study drug for agitation in Alzheimer’s dementia with caregiver support

This Phase 2 trial tests a study medicine to reduce “agitation” behaviors in people with Alzheimer’s dementia. You and your caregiver would complete required assessments and may need genetic and blood testing to check how the body handles the drug.

Maitland, Florida
NCT04516057Recruiting· Phase 3
Tested medicine nabilone for agitation in Alzheimer’s dementia

This Phase 3 trial studies whether nabilone can reduce agitation (restlessness, anger, or difficult behavior) in people with Alzheimer’s dementia. It’s designed for older adults who already have agitation despite standard dementia care.

Calgary, Alberta
NCT06014424Recruiting· Phase 2
CBD medication study for agitation in Alzheimer's

This study tests if a CBD medication can help reduce agitation in people with Alzheimer's disease. It's for adults 55 and older who have significant agitation and mild to moderate dementia.

Calgary, Alberta
NCT07011732Recruiting· Phase 3
Testing a drug for Alzheimer's-related agitation

This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.

Scottsdale, Arizona
NCT04629547Recruiting· Phase 2
Sleep study to help prevent Alzheimer’s disease

This trial tests whether treating sleep issues and measuring sleep can help lower the risk of Alzheimer’s disease before it starts. It focuses on older adults with no dementia signs yet.

St Louis, Missouri

Hear when a new Alzheimer Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.